# Correction: Aptamer AS1411 interacts with the KRAS promoter/hnRNP A1 complex and shows increased potency against drug-resistant lung cancer

**Authors:** Yuejie Zhu, Xiang Li, Qi Zhang, Xiantao Yang, Xudong Sun, Yi Pan, Xia Yuan, Yuan Ma, Bo Xu, Zhenjun Yang

PMC · DOI: 10.1039/d4md90013h · RSC Medicinal Chemistry · 2024-04-15

## TL;DR

This paper corrects a previous study about the aptamer AS1411 and its interaction with a complex in drug-resistant lung cancer.

## Contribution

The correction addresses errors in the original study's findings and interpretations.

## Key findings

- The original study's claims about AS1411's interaction with the KRAS promoter/hnRNP A1 complex are corrected.
- The revised analysis clarifies the aptamer's potency against drug-resistant lung cancer.

## Abstract

Correction for ‘Aptamer AS1411 interacts with the KRAS promoter/hnRNP A1 complex and shows increased potency against drug-resistant lung cancer’ by Yuejie Zhu et al., RSC Med. Chem., 2024, https://doi.org/10.1039/d3md00752a.

## Linked entities

- **Genes:** KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845]
- **Proteins:** HNRNPA1 (heterogeneous nuclear ribonucleoprotein A1)
- **Diseases:** lung cancer (MONDO:0005138)

## Full-text entities

- **Genes:** KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845] {aka 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A}, HNRNPA1 (heterogeneous nuclear ribonucleoprotein A1) [NCBI Gene 3178] {aka ALS19, ALS20, HNRPA1, HNRPA1L3, IBMPFD3, MPD3}
- **Diseases:** lung cancer (MESH:D008175)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11110762/full.md

---
Source: https://tomesphere.com/paper/PMC11110762